Skip to main content
. 2016 Feb 21;7(13):15959–15976. doi: 10.18632/oncotarget.7557

Figure 9. Influence of AZD5363 monotherapy in tumor progression and performance status in a late-stage model of mouse prostate cancer.

Figure 9

A., Comparison of individual outcomes for PTEN/P53-DKO mice randomized to control or AZD5363 (M0, no metastasis present; M1, metastasis present; PS (+), favorable performance status; PS (−), poor performance status). Kaplan-Meier plots of overall survival for PTEN/P53-DKO control and AZD5363 treated versus the presence of metastasis B. and performance status C..